Abstracts Archive - Page 1725 of 2607 - ACR Meeting Abstracts

Abstract Number: 1889 • 2016 ACR/ARHP Annual Meeting
Predictors of Acro-Osteolysis in Systemic Sclerosis
Ashraf Raslan¹ and Vivien Hsu², ¹Medicine, Rutgers-RWJ Medical School, Jersey City, NJ, ²Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ
Background/Purpose: Acro-osteolysis (AO) is the bony resorption on the distal tufts of the digits, a characteristic radiological finding in Systemic Sclerosis (SSc) with estimated prevalence…
Abstract Number: 1890 • 2016 ACR/ARHP Annual Meeting
Functional Disability and Its Predictors in Systemic Sclerosis: A Study from the Desscipher Project within the European Scleroderma Trials and Research Group
Veronika K. Jaeger¹, Lazlo Czirjak², Veronika Lóránd², Gabriele Valentini³, Serena Vettori⁴, Francesco Del Galdo⁵, Giuseppina Abignano⁶, Oliver Distler⁷, Britta Maurer⁷, Christopher Denton⁸, Svetlana Nihtyanova⁹, Yannick Allanore¹⁰, Jerome Avouac¹¹, Gabriela Riemekasten¹², Elise Siegert¹³, Dörte Huscher¹⁴, Marco Matucci-Cerinic¹⁵, Serena Guiducci¹⁶, Marc Frerix¹⁷, Ingo H. Tarner¹⁸, Beata Garay-Toth¹⁹, Lidiya P. Ananieva²⁰, Franco Cozzi²¹, Sule Yavuz²², Nicolas Hunzelmann²³, Alessandra Vacca²⁴, Tim Schmeiser²⁵, Simona Rednic²⁶, Valeria Riccieri²⁷, Brigitte Krummel-Lorenz²⁸, Armando Gabrielli²⁹, Paloma Garcia De La Peña³⁰, Codrina Ancuta³¹, Ulf Müller-Ladner³², Ulrich A. Walker¹ and on behalf of the DeSScipher Consortium and contributing EUSTAR centres, ¹Department of Rheumatology, University Hospital Basel, Basel, Switzerland, ²Department of Rheumatology and Immunology, University of Pécs, Pécs, Hungary, ³Internal and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy, ⁴Department of Internal and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶Clinical and Experimental Medicine, Second University of Naples, Napoli, Italy, ⁷Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁸Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁹Centre for Rheumatology and Connective Tissue Diseases, University College London Medical School, Royal Free Hospital, London, United Kingdom, ¹⁰Rheumatology, Paris Descartes University, Paris, France, ¹¹Department of Rheumatology, University of Paris Descartes, Paris, France, ¹²Department of Rheumatology, Universitatsklinikum Schleswig-Holstein, Lubeck, Germany, ¹³Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, ¹⁴Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ¹⁵Department of Medicine, Division of Rheumatology, University of Florence, Florence, Italy, ¹⁶Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Florence, Italy, ¹⁷Department of Rheumatology and Clinical Immunology, Justus-Liebig-University Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, ¹⁸Rheumatology and Clinical Immunology, Justus-Liebig-University of Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, ¹⁹FESCA, Budapest, Hungary, ²⁰Microcirculation and Inflammation, Research Institute of Rheumatology RAMS, Moscow, Russia, ²¹Division of Rheumatology, University Hospital of Padova, Padova, Italy, ²²Marmara University Faculty of Medicine, Rheumatology, Istanbul, Turkey, ²³Department of Dermatology, University of Cologne, Cologne, Germany, ²⁴University Hospital of Cagliari, Rheumatology Unit, Monserrato, Italy, ²⁵Krankenhaus St. Josef, Wuppertal, Germany, ²⁶Rheumatology, Emergency County Clinical Hospital Cluj Napoca, Cluj-Napoca, Romania, ²⁷Cattedra di Reumatologia, Dip Clinica e Terapia Medica, Sapienza Università di Roma, Roma, Italy, ²⁸Rheumatologist, Frankfurt, Germany, ²⁹Istituto di Clinica Medica Generale, Ematologia ed Immunologia Clinica, Università Politecnica delle Marche, Ancona, Italy, ³⁰Rheumatology, Hospital Madrid Norte Sanchinarro, Madrid, Spain, ³¹G.T.Popa Center for Biomedical Research, Iasi, Romania, ³²Justus-Liebig-University Giessen, Department of Internal Medicine and Rheumatology, Kerckhoff-Klinik, Bad Nauheim, Germany, Bad-Nauheim, Germany
Background/Purpose: Systemic sclerosis (SSc) can greatly impact the patients’ quality of life due to its multisystem manifestations. The health assessment questionnaire (HAQ) is one of…
Abstract Number: 1891 • 2016 ACR/ARHP Annual Meeting
Excellent Reliability of Semiquantitative Nailfold Capillaroscopy Assessment in a Systemic Sclerosis Cohort – a Pilot Study
Ana Maria Gheorghiu, Raida Oneata, Alina Soare, Rucsandra Dobrota, Liviu Macovei, Mihaela Milicescu, Mariana Sasu, Marilena Gorga, Ioan Ancuta, Mihai Bojinca, Victor Stoica and Carina Mihai, Carol Davila University of Medicine and Pharmacy, Internal Medicine and Rheumatology Department, Cantacuzino Clinical Hospital, Bucharest, Romania
Background/Purpose: Nailfold capillaroscopy (NFC) is essential in the evaluation and classification of systemic sclerosis (SSc). Semiquantitative capillaroscopy scoring is a promising tool for assessing disease…
Abstract Number: 1892 • 2016 ACR/ARHP Annual Meeting
Immunosignature Technology Differentiates Patients with Systemic Sclerosis and Internal Organ Involvement
Lorinda Chung¹, David Fiorentino², Robert Gerwien³, Kathleen Jia⁴, Joseph Barten Legutki³, Antonio Valenzuela Vergara⁴, Lisa Zhu⁴, Theodore M. Tarasow³ and Kathryn Sykes³, ¹Rheumatology, Stanford University Medical Center, Palo Alto, CA, ²Department of Dermatology, Stanford University School of Medicine, Palo Alto, CA, ³HealthTell, Inc, san ramon, CA, ⁴Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease (CTD) characterized by fibrosis, vascular complications, and inflammation affecting both skin and internal organs. Diagnosis of…
Abstract Number: 1893 • 2016 ACR/ARHP Annual Meeting
Prevalence of Antiphospholipid Antibodies in Systemic Sclerosis: A Systematic Review and Meta-Analysis
Angélique Lemaire^1,2, Vincent Sobanski^2,3,4,5, Luc Dauchet⁶, Eric Hachulla^1,2,3,5, Sylvain Dubucquoi^3,5,7, Marc Lambert^1,2,3,5, Pierre-Yves Hatron^1,2,8 and David Launay^1,2,3,5, ¹CHU Lille, Département de Médecine Interne et Immunologie Clinique, F-59000 Lille, France, Lille, France, ²CHU Lille, Centre national de référence maladies systémiques et auto-immunes rares (sclérodermie systémique), F-59000 Lille, France, Lille, France, ³Inserm, U995, F-59000 Lille, France, Lille, France, ⁴CHU Lille, Département de Médecine Interne et Immunologie Clinique, F-59000 Lille, France, ⁵Univ. Lille, U995, Lille Inflammation Research International Center (LIRIC), F-59000 Lille, France, Lille, France, ⁶CHU Lille, Service d’Epidémiologie, économie de la santé et prevention, F-59000 Lille, France, Lille, France, ⁷CHU Lille, Laboratoire d’Immunologie, F-59000 Lille, France, Lille, France, ⁸Univ Lille, CHU Lille, F-59000 Lille, France, Lille, France
Background/Purpose: Antiphospholipid antibodies (aPL) can be present in the sera of systemic sclerosis (SSc) patients. Important variations of their prevalence are observed in the literature.…
Abstract Number: 1894 • 2016 ACR/ARHP Annual Meeting
Increased Mortality in Systemic Sclerosis Patients with Fibrosing Myopathy
Julie J. Paik¹, Fredrick M. Wigley², Ami A. Shah¹, Andrea Corse³, Laura K. Hummers⁴ and Andrew Mammen⁵, ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheum Div/Mason F Lord, Johns Hopkins University School of Medicine, Baltimore, MD, ³Neurology, Johns Hopkins University, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Skeletal myopathy in systemic sclerosis (SSc) is associated with poor outcomes such as disability. The spectrum of muscle histopathology of weak SSc patients is…
Abstract Number: 1895 • 2016 ACR/ARHP Annual Meeting
Increased CXCL4/PF4 Presence in Systemic Sclerosis and Absence of Heparin Directed Autoantibodies
Boyang Zheng¹, Normand Blais², Jean-Luc Senécal³, Gemma Perez⁴ and Martial Koenig⁵, ¹Division of Internal Medicine, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada, ²Hematology, Hôpital Notre-Dame du CHUM, Montreal, QC, Canada, ³Université de Montréal, Montréal, QC, Canada, ⁴Laboratory of autoimmunity, Centre de Recherche du CHUM, Montreal, QC, Canada, ⁵Internal Medicine, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada
Background/Purpose: Platelet factor 4 (PF4), also called CXLC4 is a chemokine that is found in higher levels in systemic sclerosis (SSc) patients and is in…
Abstract Number: 1896 • 2016 ACR/ARHP Annual Meeting
Efficacy of Pulmonary Arterial Hypertension-Specific Drugs Combination Therapy in Survival of Patients with Pulmonary Arterial Hypertension Associated with Systemic Sclerosis and Other Connective Tissue Diseases
Sumiaki Tanaka¹, Yu Matsueda¹, Gakuro Abe², Jun Okada³ and Shunsei Hirohata¹, ¹Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ²Kitasato University School of Medicine, Sagamihara, Japan, ³Nutritional management, Kitasato Junior Collage of health and Hygienic Sciences, Minami-Uonuma, Japan
Background/Purpose: Survival of patients with pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD), especially systemic sclerosis (SSc), is poorer than that of patients…
Abstract Number: 1897 • 2016 ACR/ARHP Annual Meeting
Vitamin-D Levels and Gastrointestinal (GI) Manifestations in Systemic Sclerosis (SSc)
Suzanne Kafaja¹, Aly Aly², Yossra A Suliman³, Mohamed Alemam⁴, Philip J. Clements⁵ and Daniel E. Furst⁶, ¹Medicine/Rheumatology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Chamblion St,, Alexandria Faculty of Medicine, Alexandria, Egypt, ³Rheumatology and Rehabilitation dept., Rheumatology and Rehabilitation dept. Assiut university hospital, Assiut Egypt, Assiut, Egypt, ⁴Clinical Pathology and Laboratory Medicine Department, Assistant Lecturer, Qena, Egypt, ⁵Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: The GI tract is one of the most commonly affected systems in SSc patients. GI disease in SSc patients is thought to be multifactorial…
Abstract Number: 1898 • 2016 ACR/ARHP Annual Meeting
The Lack of Association of Osteoporosis with Proton Pump Inhibitor in Scleroderma: A UK Single Centre Cohort Experience
Ana Afonso¹, Svetlana Nihtyanova², Christopher Denton³ and Voon H. Ong⁴, ¹Internal Medicine, Hospital Pedro Hispano, EPE, Porto, Portugal, ²Centre for Rheumatology and Connective Tissue Diseases, University College London Medical School, Royal Free Hospital, London, United Kingdom, ³Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁴Rheumatology, UCL Division of Medicine, London, United Kingdom
Background/Purpose: Recent studies suggest that proton pump inhibitor (PPI) use is variably associated with risk of osteoporosis. The aim of this study was to investigate…
Abstract Number: 1899 • 2016 ACR/ARHP Annual Meeting
The Intestinal Involvement in Systemic Sclerosis Is Characterized By a Peculiar Gut Microbiota
Silvia Bosello¹, Francesco Paroni Sterbini², Gerlando Natalello¹, Giovanni Canestrari¹, Federico Parisi¹, Maurizio Sanguinetti³ and Gianfranco Ferraccioli⁴, ¹Division of Rheumatology, Università Cattolica - Fondazione Policlinico Universitario A.Gemelli, Rome, Italy, ²Institute of Microbiology, Università Cattolica - Fondazione Policlinico Universitario A.Gemelli, Rome, Italy, ³Institute of Microbiology, Università Cattolica - Fondazione Policlinico Universitario A Gemelli, Rome, Italy, ⁴Division of Rheumatology - Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: Gastrointestinal involvement is recognized as a major cause of morbidity and mortality in systemic sclerosis (SSc). The pathophysiology is still unclear and includes impairment…
Abstract Number: 1900 • 2016 ACR/ARHP Annual Meeting
Anti-Topoisomerase Positive Systemic Sclerosis – Prognosis Infaust?
Maaike Boonstra¹, Gaia A. Beerends², Hans U. Scherer², Tom W.J. Huizinga¹ and Jeska K. de Vries-Bouwstra¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Anti-topoisomerase antibodies (ATA) in systemic sclerosis have been associated with poorer prognosis including diffuse skin involvement, pulmonary fibrosis, cardiac involvement and increased mortality. However,…
Abstract Number: 1901 • 2016 ACR/ARHP Annual Meeting
Screening for Pulmonary Arterial Hypertension in an Unselected Prospective Systemic Sclerosis Cohort
Els Vandecasteele¹, Benny Drieghe², Karin Melsens³, Kristof Thevissen², Michel De Pauw⁴, Ellen Deschepper⁵, Saskia Decuman⁵, Karolien Bonroy², Yves Piette⁶, Filip De Keyser⁵, Guy Brusselle² and Vanessa Smith², ¹Dep ofCcardiology, University Hospital Ghent, Ghent, Belgium, ²University Hospital Ghent, Ghent, Belgium, ³Department of Internal Medicine, Ghent University, Ghent, Belgium, ⁴Dep of cardiology, University Hospital Ghent, Ghent, Belgium, ⁵Ghent University, Ghent, Belgium, ⁶Dep of Rheumatology, University Hospital Ghent, Ghent, Belgium
Background/Purpose: Screening for pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc) improves outcome. The DETECT screening algorithm (DETECT-algorithm) is recommended in a high-risk SSc subgroup.…
Abstract Number: 1902 • 2016 ACR/ARHP Annual Meeting
Detecting the Pulmonary Vascular Involvement and the Changes in Gene Activation Profiles at Early Stage of Systemic Sclerosis in Patients with Raynaud Phenomenon
Yoshinobu Koyama¹, Soichiro Fuke², Yoshiharu Sato³ and Toshie Higuchi⁴, ¹Division of Rheumatology, Japan Red Cross Okayama Hospital, Okayama, Japan, ²Department of Cardiology, Japan Red Cross Okayama Hospital, Okayama, Japan, ³DNA Chip Research Inc, Yokohama, Japan, ⁴Center for Autoimmune Diseases, Division of Rheumatology, Japan Red Cross Okayama Hospital, Okayama, Japan
Background/Purpose: Raynaud phenomenon (RP) is known to precede other disease manifestations of systemic sclerosis (SSc), and classically viewed as reversible vasospasm due to functional changes…
Abstract Number: 1903 • 2016 ACR/ARHP Annual Meeting
Determining Disease Course in Localized Scleroderma: A Prospective Cohort Study
Jack O'Brien¹ and Heidi Jacobe², ¹Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, USA, Dallas, TX, ²Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Localized scleroderma (LS) is characterized by skin sclerosis, producing devastating impairment in those affected. It was previously thought to “burn out” within 5 years,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].